UNOMR
Developing single-molecule protein analysis using nanopore sensors, AI, and silicon-based hardware for drug discovery and diagnostics.
Website: https://unomr.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | UNOMR |
| Tagline | Developing single-molecule protein analysis using nanopore sensors, AI, and silicon-based hardware for drug discovery and diagnostics. |
| Headquarters | Zurich, Switzerland |
| Founded | 2022 |
| Stage | Seed |
| Business model | Hardware + Software |
| Industry | Deeptech |
| Technology type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Academic Spinout |
| Funding label | Seed |
| Total disclosed | $353,000 (pre-seed and seed funding disclosed across BRIDGE and Venture Kick) [BioIncubate] [Venture Kick, November 2024] [StartupTicker, April 2025] |
Links
Open sources
- LinkedIn: https://www.linkedin.com/company/unomr
- Careers: https://unomr.com/careers
What an Investor Needs First
PUBLIC UNOMR is an ETH Zürich spin-off building a single-molecule protein analysis platform around nanopore sensors, silicon-based hardware, and data analysis, a combination that merits attention because it targets a well-recognized measurement bottleneck in proteomics while still early enough for technical and commercial proof points to move the story materially [ETH Zürich, April 2026] [Venture Leaders, May 2026]. Founded in 2022 according to the structured company record, the company emerged from ETH Zürich’s Laboratory for Biosensors and Bioelectronics, where co-founders Til Schlotter, Julian Hengsteler, and Julia Wagner completed their doctorates and translated academic work into a venture-backed spin-out effort [ETH Zürich, April 2026] [ETH Zürich, July 2026].
The product case rests on a patented serial or interface nanopore sensor that the company says can detect protein modifications at the single-molecule level, with an initial focus on glycosylation and a longer-term ambition to make proteins more directly readable in a sequencing-like workflow [Venture Kick, November 2024] [StartupTicker, April 2025] [ETH Zürich, April 2026]. That is a consequential claim if validated in customer settings, because UNOMR argues its platform can work with small sample volumes and low protein concentrations while being manufactured on silicon using standard lithographic processes, which would matter for both usability and scale [Venture Kick, April 2025] [Innovationspark Ost, February 2024].
The team appears well matched to the early technical brief. Schlotter is presented as leading application development, customer interaction, and fundraising, Hengsteler leads engineering across sensor hardware, software, microfluidics, and data analysis, and Wagner brings operational and venture-oriented experience alongside her technical training [ETH Zürich, April 2026] [Global Innovation Summit 2026] [Venture Kick, November 2024].
Capital formation remains modest but visible: public sources indicate support from the BRIDGE program, CHF 40,000 from Venture Kick in November 2024, and CHF 150,000 from Venture Kick in April 2025, consistent with a company still in grant and pre-commercial financing mode rather than a fully institutional seed syndicate [BioIncubate] [Venture Kick, November 2024] [StartupTicker, April 2025]. The business model is best read as hardware plus software for research and applied life sciences users, with early stated markets spanning pharma, biotech, diagnostics, food, and academia [ETH Zürich, April 2026] [Venture Leaders, May 2026].
Over the next 12 to 18 months, the key questions are straightforward: whether UNOMR can place early-access devices into real customer testing, show repeatable performance on glycosylation and adjacent protein-modification use cases, and convert program support into a clearer financing path and fabrication roadmap [StartupTicker, April 2025] [German Chips Competence Centre, August 2026] [LinkedIn, May 2026]. Public evidence is encouraging on technical ambition and founder-market fit, but the decisive de-risking steps are still ahead.
Partially corroborated -- Relies on multiple public sources, but several material product and team claims remain company-linked or profile-based rather than independently validated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Seed |
Inside the Company
PUBLIC
The cleanest way to understand UNOMR is as an ETH Zürich spin-off that is still early, but already legible in its institutional footprint. Public materials tie the company to Zurich, Switzerland, describe it as founded in 2022, and place its origins in ETH Zürich's Laboratory for Biosensors and Bioelectronics, where co-founders Til Schlotter, Julian Hengsteler, and Julia Wagner completed doctoral work before forming the company around nanopore-based protein analysis [LinkedIn] [ETH Zürich, April 2026].
The milestone record is thin but reasonably chronological. Innovationspark Ost listed the company among its funded startups in February 2024 and described a silicon-sensor approach intended for scalable protein analysis [Innovationspark Ost, February 2024]. Venture Kick then announced a CHF 40,000 award in November 2024 [Venture Kick, November 2024], followed by StartupTicker's April 2025 report of a further CHF 150,000 Venture Kick award to support hiring, business development, and preparation for customer testing [StartupTicker, April 2025]. By July 2026, ETH Zürich reported that the spin-off had won the Hello Tomorrow Challenge, which stands as the latest dated public milestone in the source set [ETH Zürich, July 2026].
Partially corroborated -- Confirmed by ETH Zürich and company LinkedIn for founding context, with milestone support from Innovationspark Ost, Venture Kick, StartupTicker, and ETH Zürich.
Under the Hood
MIXED
The company is building a protein-analysis platform around a nanopore sensor rather than a conventional bulk proteomics workflow. Public descriptions from ETH Zürich, Venture Kick, and StartupTicker converge on the same core claim: UNOMR’s patented serial, or interface, nanopore sensor is designed to detect protein modifications at the single-molecule level through ionic-current measurements, with an initial focus on glycosylation analysis [ETH Zürich, April 2026] [Venture Kick, April 2025] [StartupTicker, April 2025]. The stated longer-term ambition is broader protein readability analogous to what sequencing did for DNA, but the nearer-term product framing is narrower and more concrete, namely high-resolution analysis of protein modifications for drug discovery, diagnostics, food science, and research use cases [ETH Zürich, April 2026] [StartupTicker, April 2025].
The technical architecture described in public sources pairs the sensor with chemistry, silicon-based hardware, and data analysis, with scalability tied to use of standard lithographic processes on silicon sensors [Innovationspark Ost, February 2024] [ETH Zürich, April 2026]. Venture Kick also attributes several practical claims to the platform, including small sample-volume requirements, low protein concentrations, and relatively basic sample purification, though those points should still be read as company-linked performance assertions rather than third-party benchmark data [Venture Kick, April 2025]. More recently, the German Chips Competence Centre said it is helping UNOMR identify European fabrication pathways for the sensor chip, which is a useful signal that manufacturability is part of the present product work rather than a distant research question [German Chips Competence Centre, August 2026].
Public evidence on commercialization remains early but directionally relevant. A LinkedIn post cited in the research says the company is getting closer to putting an early-access device into customers' hands for on-site testing, and StartupTicker reported in April 2025 that Venture Kick funding would support preparation for customer testing; neither source, however, confirms broad deployment or published validation data from external users [LinkedIn] [StartupTicker, April 2025]. That leaves the central diligence question unchanged: the technical proposition is differentiated on paper, but public materials do not yet establish reproducible throughput, accuracy, or workflow advantages against existing proteomics methods.
Partially corroborated -- Product claims are corroborated across ETH Zürich, Venture Kick, StartupTicker, and Innovationspark Ost, but core performance details remain largely company-linked and external validation is limited.
Market Research
PUBLIC
Proteomics is attracting fresh attention because biology still reads proteins far less directly than it reads DNA, and UNOMR is positioning itself against that gap rather than against a narrow point solution [ETH Zürich, April 2026] [Venture Leaders, May 2026]. The public record here is thin on third-party market sizing, so the market view has to stay conservative and source-led. What is visible is that the company is targeting a broad research and diagnostics-adjacent workflow spanning pharmaceutical and biotechnology companies, medtech and diagnostics developers, food innovators, and academic labs, with glycosylation analysis as the initial commercial wedge [ETH Zürich, April 2026] [StartupTicker, April 2025] [Venture Leaders, May 2026].
The only explicit sizing claim tied to UNOMR in the available material comes from StartupTicker, which reported the company "ambits to capture up to 50% of the market" as an enabling technology for next-generation proteomics [StartupTicker, April 2025]. That is a company-linked ambition rather than an independently validated market model, so it should be read as directional, not analytical. A more defensible interpretation is that UNOMR is pursuing a subset of the broader proteomics tools market where researchers need higher-resolution information on protein modifications, especially glycosylation, and where small sample volumes and lower concentration requirements could matter if the platform performs as described [Venture Kick, April 2025].
| Sizing or scope claim | Figure | Interpretation |
|---|---|---|
| Company ambition in next-generation proteomics | Up to 50% | Company-reported aspiration, not independent TAM validation [StartupTicker, April 2025] |
| Initial application focus | Glycosylation | Narrower entry point within broader proteomics workflows [ETH Zürich, April 2026] [Venture Kick, April 2025] |
The table underscores the central limitation in this section: there is clear evidence of category ambition, but not yet a third-party market model that would let investors map TAM, SAM, and realistic near-term SOM with precision. For now, the more useful lens is workflow fit, where a focused initial use case is easier to underwrite than a platform claim spanning multiple end markets.
Demand drivers are easier to substantiate than market size. Across ETH Zürich, Venture Kick, and Venture Leaders coverage, the recurring theme is that existing proteomics workflows do not give direct enough visibility into protein modifications, creating a technical opening for single-molecule approaches that can inspect structure and modification state with less sample input and simpler preparation requirements [ETH Zürich, April 2026] [Venture Kick, April 2025] [Venture Leaders, May 2026]. That matters most in drug discovery and translational research, where glycosylation and other post-translational modifications can affect efficacy, safety, and manufacturability, and in food and applied life science settings where protein characterization can influence product development [StartupTicker, April 2025] [ETH Zürich, April 2026].
Adjacent markets also help explain the opportunity set. UNOMR's longer-term framing, making proteins readable in a way analogous to DNA sequencing, places it near sequencing, analytical instrumentation, and bioinformatics rather than in a pure wet-lab consumables niche [ETH Zürich, April 2026]. The substitute set today is likely conventional proteomics and other protein-analysis workflows rather than another directly named nanopore protein company, because no named direct competitors were confirmed in the provided sources. That makes the commercial question less about headline category size and more about whether a new instrument stack can fit existing lab economics, validation standards, and software workflows.
Regulatory and macro forces cut both ways. On the positive side, public support from BRIDGE, Venture Kick, and the German Chips Competence Centre suggests that European innovation programs currently view the sensor and fabrication stack as strategically relevant, which is notable for a hardware-plus-biology company developing silicon-based chips [BioIncubate] [Venture Kick, November 2024] [German Chips Competence Centre, August 2026]. The same facts also point to a practical constraint: if the product path depends on specialized fabrication, assay validation, and eventual use in regulated research or diagnostics contexts, commercialization timelines may be shaped as much by manufacturing readiness and application proof as by raw scientific novelty [Innovationspark Ost, February 2024] [ETH Zürich, April 2026].
Reasoned from indirect evidence -- Market scope is supported by multiple public sources, but explicit sizing is limited to a company-linked aspiration reported by StartupTicker, with no independent third-party TAM model in the cited material.
Competition and Substitutes
MIXED UNOMR appears to sit in a narrow but ambitious part of the proteomics stack, competing less with a single named startup peer in the public record than with existing protein-analysis workflows that are already embedded in pharma, biotech, diagnostics, food R&D, and academic labs [ETH Zürich, April 2026] [StartupTicker, April 2025].
The public sourcing does not name direct venture-backed competitors, so the clearest way to map the field is by method class rather than cap table. Incumbents are the established proteomics toolchains that already answer many of the buyer questions UNOMR wants to address, particularly protein-modification analysis and characterization in research and development settings [ETH Zürich, April 2026] [Venture Leaders, May 2026]. Adjacent substitutes include broader analytical workflows used in drug discovery, diagnostics development, and food science, where users may accept less direct single-molecule readout if the incumbent method is validated, easier to procure, or already integrated into lab operations [StartupTicker, April 2025] [Innovationspark Ost, February 2024]. Challengers, at least from the public evidence, are not well enumerated by name, but the category framing is clear: next-generation proteomics platforms that promise more direct, higher-resolution protein readout than conventional approaches [StartupTicker, April 2025] [ETH Zürich, July 2026].
Where UNOMR has a credible edge today is technical distinctiveness rather than distribution. Multiple public sources describe a patented serial or interface nanopore sensor designed to detect protein modifications at the single-molecule level, with an initial focus on glycosylation, and describe a hardware approach based on silicon sensors and standard lithographic processes [Venture Kick, November 2024] [StartupTicker, April 2025] [Innovationspark Ost, February 2024]. That matters because a platform that can work with small sample volumes, low protein concentrations, and basic sample purification could reduce workflow friction if performance holds up in customer environments [Venture Kick, April 2025]. The durability of that edge is still uncertain. The patent position, ETH spinout pedigree, and chip-fabrication support from the German Chips Competence Centre suggest some defensibility on talent and technical know-how, but the company remains early enough that the advantage is perishable if larger tool vendors or better-capitalized proteomics platforms reach practical deployment first [ETH Zürich, April 2026] [German Chips Competence Centre, August 2026].
The exposure is easier to see than the moat. UNOMR does not appear, from public material, to control a scaled commercial channel, an installed base, or a large public financing cushion, and its disclosed non-dilutive and early-stage funding remains modest in absolute terms [BioIncubate] [Venture Kick, November 2024] [StartupTicker, April 2025]. That leaves the company vulnerable to adjacent winners that can bundle new protein-analysis capabilities into trusted laboratory procurement paths, or to incumbent methods that remain good enough for regulated and research use cases. The company also looks most exposed in categories where buyers value validated workflow integration over novel readout depth, since the public record points to early-access and on-site testing preparation rather than broad deployment already in market [Moneycab, April 2025] [LinkedIn] [ETH Zürich, April 2026].
The most plausible 18-month scenario is that the competitive field remains defined by proof points rather than market share. If UNOMR can convert its early-access device into credible on-site testing, especially in glycosylation-focused use cases where current workflows are costly or indirect, it is a plausible winner if performance and ease of sample handling translate outside the lab that invented the technology [LinkedIn] [Venture Kick, April 2025]. The more likely loser if that translation slips is not a named startup in the public file, but UNOMR itself: in a market where incumbent analytical workflows already have budgets and buyer trust, a company without disclosed large-scale commercial traction can lose time faster than it loses headline visibility [ETH Zürich, April 2026] [Venture Leaders, May 2026].
Reasoned from indirect evidence -- Competitive mapping rests on public company, university, and grant-program sources, but the available evidence does not name direct competitors or independently benchmark UNOMR against specific alternative platforms.
Opportunity
Opportunity framing
PUBLIC The prize here is unusually large for a company at this stage, because a working single-molecule protein readout platform could become a foundational tool for how drug developers, diagnostics teams, and research labs measure protein structure and modification, a workflow that remains materially harder than DNA sequencing today according to the company profile and spinout coverage [ETH Zürich, April 2026] [Venture Leaders, May 2026].
The headline opportunity is not simply to sell another lab instrument. It is to establish a new measurement layer for proteomics, starting with glycosylation and other protein modifications, then moving toward broader protein readout if the sensor architecture scales as described [Venture Kick, April 2025] [ETH Zürich, April 2026]. That outcome is still early, but it is not purely aspirational on the public record: multiple sources describe a patented serial or interface nanopore sensor, an initial application wedge in glycosylation, small-sample requirements, and silicon-based fabrication pathways that could matter if the product moves from bespoke research use into repeatable chip production [Venture Kick, April 2025] [Innovationspark Ost, February 2024] [German Chips Competence Centre, August 2026].
A second reason the upside is reachable is that the company appears to be choosing an entry point narrow enough to validate in the field. Rather than claiming full protein sequencing from day one, UNOMR is publicly focused on high-resolution protein-modification analysis, especially glycosylation, while signaling interest from pharma, biotech, diagnostics, food, and academic buyers [ETH Zürich, April 2026] [StartupTicker, April 2025]. That sequencing of the product roadmap matters, because category-defining platform companies in tools markets often begin by solving one painful assay better than incumbents before broadening menu, throughput, and end-market coverage.
Growth scenarios
PUBLIC The public evidence supports a small set of upside paths, each dependent on different proof points.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Glycosylation wedge becomes a standard assay | UNOMR becomes a preferred platform for single-molecule glycosylation analysis in drug discovery, biologics characterization, and translational research | Early access device testing converts into repeat research workflows and published validation with external users [David Sommer - BarrelWise Technologies | LinkedIn, 2026] [StartupTicker, April 2025] | The company is already positioning glycosylation as its first focused use case, and public materials say the platform works with small sample volumes and basic purification, traits that could lower adoption friction if reproduced in customer settings [Venture Kick, April 2025] [ETH Zürich, April 2026] |
| Sensor platform becomes OEM or lab infrastructure | The silicon nanopore chip becomes embedded in third-party instruments, diagnostic workflows, or contract research environments rather than sold only as a standalone platform | A fabrication and packaging milestone with European chip pathways enables repeatable sensor supply and integration [Innovationspark Ost, February 2024] [German Chips Competence Centre, August 2026] | The company's platform is described as silicon-based and compatible with standard lithographic processes, which is the clearest public signal that the technology may be manufacturable beyond a one-off academic prototype [Innovationspark Ost, February 2024] |
| Proteomics readout expands beyond the initial assay wedge | UNOMR extends from modification analysis into a broader protein-readability platform, with a product category closer in strategic value to sequencing infrastructure than to a single assay kit | Technical validation that the interface nanopore approach can generalize from glycosylation to wider protein-structure or sequence information [ETH Zürich, April 2026] [Venture Leaders, May 2026] | Public sources consistently frame the long-term ambition as making proteins readable in a manner analogous to DNA sequencing, while the current wedge is narrow enough to establish technical credibility first [ETH Zürich, April 2026] [Venture Kick, April 2025] |
The table shows that the same core asset can support more than one scaling route. The first path is the most direct commercially, the second is more infrastructure-like, and the third carries the largest upside but also depends on the biggest technical expansion from what is publicly demonstrated today.
What compounding looks like
PUBLIC If this works, compounding likely comes from a measurement-data and workflow flywheel rather than a classical consumer network effect. Each external deployment can generate more assay data, more sample-specific signal interpretation, and more evidence on where the sensor outperforms incumbent proteomics workflows, which in turn can sharpen software, analysis, and customer targeting [ETH Zürich, April 2026] [Venture Leaders, May 2026].
There are early public hints that this flywheel is beginning, even if still pre-scale. UNOMR has said it is seeking early adopters across pharma, biotech, medicine, food development, and basic research, and separate public references indicate movement toward early access device testing and on-site customer evaluation [ETH Zürich, April 2026] [StartupTicker, April 2025] [David Sommer - BarrelWise Technologies | LinkedIn, 2026]. If those tests produce reproducible advantages on low-volume, modification-sensitive analysis, the next layer of defensibility could come from assay know-how, interpretation software, and process integration around the chip, not just the chip itself.
The manufacturing angle could compound as well. Public sources describe the sensors as silicon-based and tied to standard lithographic processes, and the German Chips Competence Centre says it is helping identify suitable European fabrication pathways [Innovationspark Ost, February 2024] [German Chips Competence Centre, August 2026]. If fabrication becomes more repeatable, product economics, reliability, and delivery timelines can all improve together, which is often what turns a promising research tool into procurement-worthy infrastructure.
The size of the win
PUBLIC A credible public market comp is not established in the provided source set, and no cited third-party market report or public peer valuation for this exact category appears in the record. The cleaner way to frame the upside is strategic rather than precise: if UNOMR were to become a trusted proteomics platform for modification analysis first, then expand toward broader protein readout, it could grow into an asset with the characteristics buyers often pay for in life-science tools, namely proprietary assay performance, embedded workflow position, and scalable consumable or chip economics (scenario, not a forecast) [ETH Zürich, April 2026] [Venture Kick, April 2025] [Innovationspark Ost, February 2024].
The most ambitious public framing comes from StartupTicker's report that the company aims to capture up to 50% of the market as an enabling technology for next-generation proteomics, but that claim is company-linked and should be treated conservatively rather than as an external market benchmark [StartupTicker, April 2025]. Even discounted heavily, the underlying point stands: if the firm can move from a specialized glycosylation tool into a broader protein-analysis platform with manufacturable silicon hardware, the outcome could be category-shaping within proteomics infrastructure rather than incremental within academic instrumentation.
Claim stands unchecked -- This section relies heavily on company-linked and ecosystem coverage, with partial corroboration from Venture Kick, StartupTicker, Innovationspark Ost, ETH Zürich, and the German Chips Competence Centre.
Sources
Open sources
[BioIncubate] UNOMR | Startup Team | https://www.bioincubate.ch/unomr
[Venture Kick, November 2024] AI to improve the healthcare system | https://www.venturekick.ch/CHF-40000-for-AI-to-improve-the-healthcare-system-streamlined-literature-review-a-platform-to-coordinate-space-traffic-and-singleprotein-sensors
[StartupTicker, April 2025] UNOMR obtains CHF 150,000 to bring a new dimension to proteomics analysis | https://www.startupticker.ch/index.php/en/news/unomr-obtains-chf-150-000-to-bring-a-new-dimension-to-proteomics-analysis
[ETH Zürich, April 2026] We are addressing a "blind spot" in biology and medicine: how UNOMR makes proteins readable | https://ee.ethz.ch/news-and-events/d-itet-news-channel/2026/04/we-are-addressing-a-blind-spot-in-biology-and-medicine-how-unomr-makes-proteins-readable.html
[Venture Leaders, May 2026] UNOMR: The Venture Leader Biotech enabling single-molecule protein analysis | https://www.venture-leaders.ch/UNOMR-The-Venture-Leader-Biotech-enabling-singlemolecule-protein-analysis
[ETH Zürich, July 2026] D-ITET spin-off UNOMR wins prestigious Hello Tomorrow Challenge | https://ee.ethz.ch/news-and-events/d-itet-news-channel/2026/07/d-itet-spin-off-unomr-wins-prestigious-hello-tomorrow-challenge.html
[Innovationspark Ost, February 2024] 2023: We present our funded startups | https://innovationspark-ost.ch/en/2023-we-present-our-funded-startups-2/
[Moneycab, April 2025] UNOMR erhält 150'000 Franken von Venture Kick | https://www.moneycab.com/finanz/unomr-erhaelt-150000-franken-von-venture-kick-um-der-proteomanalyse/
Articles about UNOMR
- UNOMR’s Single-Molecule Sensor Takes Aim at a $50 Billion Proteomics Blind Spot — The deep tech startup, backed by Swiss grants, is developing a hardware platform to analyze protein modifications for pharmaceutical and food science research.